Results 71 to 80 of about 29,053 (244)

Occupational burnout in nuclear medicine technologists working in Australia and New Zealand – results of a multi‐national survey

Journal of Medical Radiation Sciences, Volume 72, Issue 1, Page 25-33, March 2025.
Occupational burnout is associated with negative feelings about the workplace and is often caused by a high workload and a non‐supportive workplace. It is associated with absenteeism, high turnover of staff and decreased patient care. More than half of the New Zealand participants and three quarters of the Australian participants had moderate levels of
Melissa Shields, Daphne James, Lynne McCormack   +2 more
wiley   +1 more source

Prostate Cancer Theranostics – Current Evidence and Future Considerations: a Brief Overview

Acta Clinica Croatica
Despite initial response to androgen inhibition, metastatic prostate cancer is invariably an incurable disease. New agents with different mechanisms of action are needed that are capable of producing clinical benefit and prolonging survival.
Antonela Njavro, Jure Murgić, Blanka Jakšić, Marin Prpić, Angela Prgomet Sečan, Dražen Huić, Dinko Franceschi, Ana Fröbe   +7 more
doaj   +1 more source

Molecular theranostics: principles, challenges and controversies

Journal of Medical Radiation Sciences, Volume 72, Issue 1, Page 156-164, March 2025.
Molecular theranostics offers a powerful tool to drive precision medicine in nuclear oncology. While theranostics is not a new principle in nuclear medicine, recent advances in instrumentation and radiopharmacy have driven a reinvigoration and a broader suite of applications.
Geoffrey Currie
wiley   +1 more source

[177Lu-DOTA0,Tyr3]octreotate for somatostatin receptor-targeted radionuclide therapy [PDF]

, 2001
Marion de Jong, Wout A. P. Breeman, Bert F. Bernard, Willem H. Bakker, Michael Schaar, Arthur van Gameren, Joe E. Bugaj, Jack L. Erion, Michelle Schmidt, Ananth Srinivasan, Eric P. Krenning   +10 more
openalex   +2 more sources

Prospects in folate receptor-targeted radionuclide therapy

Frontiers in Oncology, 2013
Targeted radionuclide therapy is based on systemic application of particle-emitting radiopharmaceuticals which are directed towards a specific tumor-associated target. Accumulation of the radiopharmaceutical in targeted cancer cells results in high doses
Cristina eMüller, Roger eSchibli, Roger eSchibli   +2 more
doaj   +1 more source

Is it necessary to do surgical fixation in metastatic bone disease impending pathologic fracture before 177Lu-prostate-specific membrane antigen radionuclide therapy?

World Journal of Nuclear Medicine, 2021
Majid Assadi
doaj   +1 more source

Self‐Assembly of Noncanonical Peptides: A New Frontier in Cancer Therapeutics and Beyond

Macromolecular Bioscience, EarlyView.
Representative examples of noncanonical peptide assemblies in anticancer therapeutics, biomaterials, regenerative medicine, molecular imaging, and catalysis are discussed, highlighting enzyme‐instructed self‐assembly as a valuable approach for constructing biomimetic and bioinspired materials that bridge the interface between biological systems and ...
Lin Bai, Meihui Yi, Bing Xu
wiley   +1 more source

The 10% Rule in Sentinel Node Biopsy: Is Removal of All Threshold Nodes Necessary?

Otolaryngology–Head and Neck Surgery, EarlyView.
Abstract Objective Sentinel lymph node biopsy (SLNB) procedures have been guided by the “10% rule,” which stipulates that any lymph node (LN) with gamma probe activity (GPA) measured at 10% of the most radioactive sentinel lymph nodes (SLNs) should be excised.
Jake Langlie, Nicholas DiStefano, Jaylou Velez‐Torres, Carmen Gomez‐Fernandez, Russ A. Kuker, Francisco J. Civantos   +5 more
wiley   +1 more source

A minimal physiologically‐based pharmacokinetic modeling platform to predict intratumor exposure and receptor occupancy of an anti‐LAG‐3 monoclonal antibody

CPT: Pharmacometrics &Systems Pharmacology, Volume 14, Issue 3, Page 460-473, March 2025.
Abstract In oncology drug development, measuring drug concentrations at the tumor site and at the targeted receptor remains an ongoing challenge. Positron emission tomography (PET)‐imaging is a promising noninvasive method to quantify intratumor exposure of a radiolabeled drug (biodistribution data) and target saturation by treatment doses in vivo ...
Robin Michelet, Klas Petersson, Marc C. Huisman, C. Willemien Menke‐van der Houven van Oordt, Iris H. C. Miedema, Andrea Thiele, Ghazal Montaseri, Alejandro Pérez‐Pitarch, David Busse   +8 more
wiley   +1 more source

Tumor‐Targeted Radioiodinated Glyconanoparticles for Doxorubicin Delivery and Auger‐Chemotherapy in Triple‐Negative Breast Cancer

Small, EarlyView.
Combining multiple anti‐tumor therapeutic modalities using nanoparticles allows harnessing their therapeutic potential in combination with minimal side effects at lower doses. This study focuses on the development of tumor‐responsive core‐shell glyconanoparticle formulation targeting galectin‐3 in triple‐negative breast cancer (TNBC) for Auger ...
Shishu Kant Suman, Biji Balakrishnan, Madhava B. Mallia, Archana Mukherjee   +3 more
wiley   +1 more source